Gowthami Ramineni
Research Subjects
Gowthami Ramineni has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Bikramjit S. Bindra
Internal Medicine, Government Medical College and Hospital, Chandigarh, IND
1 shared publication - Dilbagh Singh
Internal Medicine, American University of Antigua, Osbourn, ATG
1 shared publication - Karan Jatwani
Department of Medical Oncology, The George Washington University Hospital, Washington, DC, USA
1 shared publication Ratesh Khillan
Hematology / Oncology, Kingsbrook Jewish Medical Center, New York, USA
1 shared publication
Latest Publications
- Open Access
- 9 September 2019
- Published by Springer Nature in Cureus
- Vol. 11 (9) , e5605
A Case of Long-term Survival of 36 Months in the Setting of Extensive-disease Small-cell Lung Cancer
Small-cell lung cancer (SCLC) is an extremely aggressive disease characterized by early regional spread and distant metastases. Patients with extensive-disease (ED) SCLC have a median survival rate of 8-11 months. Despite high response rates to initial therapy, relapses are frequent. Systemic therapy after the first-line failure remains vital in the treatment paradigm of SCLC. The National Comprehensive Cancer Network (NCCN) guidelines dictate that previously administered first-line chemotherapy can be used in relapses that occur after six months from the completion of initial therapy. For relapses within six months of initial therapy, sequential treatment with single agents is recommended. In this report, we discuss the case of a long-term SCLC survivor with an ED. The patient underwent several lines of chemotherapy and prophylactic cranial irradiation (PCI) and survived for 36 months.
- 9 September 2019
- Published by Springer Nature in Cureus
- Vol. 11 (9) , e5605
Open AccessA Case of Long-term Survival of 36 Months in the Setting of Extensive-disease Small-cell Lung Cancer
Small-cell lung cancer (SCLC) is an extremely aggressive disease characterized by early regional spread and distant metastases. Patients with extensive-disease (ED) SCLC have a median survival rate of 8-11 months. Despite high response rates to initial therapy, relapses are frequent. Systemic therapy after the first-line failure remains vital in the treatment paradigm of SCLC. The National Comprehensive Cancer Network (NCCN) guidelines dictate that previously administered first-line chemotherapy can be used in relapses that occur after six months from the completion of initial therapy. For relapses within six months of initial therapy, sequential treatment with single agents is recommended. In this report, we discuss the case of a long-term SCLC survivor with an ED. The patient underwent several lines of chemotherapy and prophylactic cranial irradiation (PCI) and survived for 36 months.